VKTX
NasdaqVIKING THERAPEUTICS, INC.
Basic Materials · Pharmaceutical Preparations
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
🔒 price chart needs market-data feed$0
2021
$0
2022
$0
2023
$0
2024
$0
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$0
Net Income—
Gross Profit—
Oper Income$-393.3M
EPS (dil)$-3.19
Rev/sh$0.00
FCF/sh—
Book/sh$5.50
Gross M—
Oper M—
Profit M—
FCF M—
ROE—
ROA—
ROIC-83.1%
R&D/Rev—
Rev Y/Y—
Rev 3Y CAGR—
EPS Y/Y-215.8%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y+3.3%
Current Ratio9.33
Quick Ratio—
Debt/Eq—
Int Coverage—
Net Debt—
Total Debt—
Cash & Eq$165.8M
Total Assets$715.7M
Oper CF$-278.7M
Capex—
Free CF—
Buybacks$6.8M
Equity$639.1M
Liabilities$76.7M
Shs Outstand0.12B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | $-55.7M | $-70.4M | $-100.8M | $-150.9M | $-393.3M |
| Net Income | $-55.0M | $-68.9M | $-85.9M | $-110.0M | $-359.6M |
| Diluted EPS | $-0.71 | $-0.90 | $-0.91 | $-1.01 | $-3.19 |
| Operating Cash Flow | $-47.6M | $-48.4M | $-73.4M | $-87.8M | $-278.7M |
| Free Cash Flow | — | — | — | — | — |
COMMUNITY · $VKTX0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.